4-[[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[4-(5-hydroxy-5-oxo-pentyl)piperazine-1-carbonyl]-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxo-butanoic acid | 1400262-74-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-[[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[4-(5-hydroxy-5-oxo-pentyl)piperazine-1-carbonyl]-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxo-butanoic acid
• 英文别名: 4-[[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[4-(4-carboxybutyl)piperazine-1-carbonyl]-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid
• CAS: 1400262-74-9
• 化学式: C₄₅H₇₂N₂O₇
• 分子量: 753.076
• InChiKey: CERDHHDWHDWMDQ-PDPDZJSCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  54
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-[[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[4-(5-hydroxy-5-oxo-pentyl)piperazine-1-carbonyl]-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxo-butanoic acid 、 1-[(2E)-3-(1,3-benzodioxol-5-yl)prop-2-enoyl]piperazine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 生成 5-[4-[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]piperazin-1-yl]-1-[4-[(E)-3-(1,3-benzodioxol-5-yl)prop-2-enoyl]piperazin-1-yl]pentan-1-one
  参考文献：
  名称：

  新桦木酸衍生物作为有效 HIV 抑制剂的设计、合成和构效关系分析

  摘要：

  桦木酸 ( 1 ) 是一种具有良好抗 HIV 活性的天然产物先导物，其先前的修饰产生了 3 - O -(3',3'-二甲基琥珀酰)桦木酸 (bevirimat, 3 )，这是一流的 HIV 成熟抑制剂。在I 期和 IIa 期临床试验中发现了3种抗性变体后，对3进行进一步修饰产生了4种，其对野生型和3种抗性 HIV-1 的活性有所提高。在优化1的持续努力中，现已设计、合成并评估了 63 种最终产品的抗 HIV-1 复制活性，以对抗 HIV-1 NL4-3感染的 MT-4 细胞系。五种已知衍生物和 21 种新衍生物与3 (EC 50 0.065 μM) 相同或更强效，而八种新衍生物与4 (EC 50 0.019 μM) 相同或更强效。这些衍生物具有扩展的结构多样性和化学空间，可以提高抗病毒活性并解决日益严重的耐药性危机。对构效关系（SAR）相关性进行了深入分析，并构建了具有高可预测性的 3D 定量

  DOI：

  10.1016/j.ejmech.2021.113287
• 作为产物：
  描述：

  5-(哌嗪-1-基)戊酸甲酯 在 4-二甲氨基吡啶 、 对甲苯磺酸 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-[[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[4-(5-hydroxy-5-oxo-pentyl)piperazine-1-carbonyl]-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxo-butanoic acid
  参考文献：
  名称：

  Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors

  摘要：

  In a continuing study of bevirimat (2), the anti-HIV-maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 mu M compared with 0.087 mu M antimaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antimaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.

  DOI：

  10.1021/jm301040s

文献信息

• Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors
  作者：Keduo Qian、Ibrahim D. Bori、Chin-Ho Chen、Li Huang、Kuo-Hsiung Lee

  DOI：10.1021/jm301040s

  日期：2012.9.27

  In a continuing study of bevirimat (2), the anti-HIV-maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 mu M compared with 0.087 mu M antimaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antimaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.
• Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors
  作者：Yu Zhao、Chin-Ho Chen、Susan L. Morris-Natschke、Kuo-Hsiung Lee

  DOI：10.1016/j.ejmech.2021.113287

  日期：2021.4

  and evaluated for anti-HIV-1 replication activity against HIV-1NL4-3 infected MT-4 cell lines. Five known and 21 new derivatives were as or more potent than 3 (EC50 0.065 μM), while eight new derivatives were as or more potent than 4 (EC50 0.019 μM). These derivatives feature expanded structural diversity and chemical space that may improve the antiviral activity and address the growing resistance crisis

  桦木酸 ( 1 ) 是一种具有良好抗 HIV 活性的天然产物先导物，其先前的修饰产生了 3 - O -(3',3'-二甲基琥珀酰)桦木酸 (bevirimat, 3 )，这是一流的 HIV 成熟抑制剂。在I 期和 IIa 期临床试验中发现了3种抗性变体后，对3进行进一步修饰产生了4种，其对野生型和3种抗性 HIV-1 的活性有所提高。在优化1的持续努力中，现已设计、合成并评估了 63 种最终产品的抗 HIV-1 复制活性，以对抗 HIV-1 NL4-3感染的 MT-4 细胞系。五种已知衍生物和 21 种新衍生物与3 (EC 50 0.065 μM) 相同或更强效，而八种新衍生物与4 (EC 50 0.019 μM) 相同或更强效。这些衍生物具有扩展的结构多样性和化学空间，可以提高抗病毒活性并解决日益严重的耐药性危机。对构效关系（SAR）相关性进行了深入分析，并构建了具有高可预测性的 3D 定量